Adenosine can be released from a variety of cells throughout the body, as the result of
increased metabolic rates, in concentrations that can have a profound impact on the …

Cells of the cardiovascular system generate and release purine nucleoside adenosine in
increasing quantities when constituent cells are “stressed” or subjected to injurious stimuli …

Multicomponent therapies, originating through deliberate mixing of drugs in a clinical setting,
through happenstance, and through rational design, have a successful history in a number …

Adenosine A2A receptor (A2AR) agonists synergize with Escherichia coli (E. coli) LPS [toll-
like receptor (TLR) 4 agonist] to up-regulate vascular endothelial growth factor (VEGF) …

Objective Low‐dose weekly methotrexate therapy remains a mainstay in the treatment of
inflammatory arthritis. Results of previous studies demonstrated that adenosine, acting at …

Activation of A2A adenosine receptors (A2ARs) protects kidneys from ischemia-reperfusion
injury (IRI). A2ARs are expressed on bone marrow–derived (BM-derived) cells and renal …

Adenosine A2A receptors were cloned about ten years ago and are known to be well
conserved among mammals. Rather selective agonists and antagonists are available. In …

We and others have shown that adenosine, acting at its receptors, is a potent modulator of
inflammation and angiogenesis. To better understand the regulation of adenosine receptors …

Abstract cDNA microarray analysis of the regions of pathologically proven different activity of
multiple sclerosis lesions was performed. Major differences in gene expression (DGE) …

Inosine is an endogenous nucleoside with immunosuppressive properties that is known to
inhibit the accumulation of proinflammatory cytokines and protect mice from endotoxin …